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1. Engineering Background 
 
The replacement of diseased hip joints with 
artificial hips is the outstanding success in 
orthopaedics in the 20th century (Skinner & Kay 
2011). Millions of these replacements have been 
implanted world-wide, delivering in most cases 
pain-relief and mobility to patients. Artificial hip 
joints replace the body’s own worn and 
diseased hip joint. 
  
Metal-on-metal joints 
Metal-on-metal hip replacements had, until very 
recently, been seen to offer improved mobility 
and longer in vivo lifetime especially for younger 
people in their 30s to 50s. 
 
 
 
 
 
 
 
 
 
However, a number of these metal-on-metal 
designs have failed earlier and in more patients 
than expected. In the ASRTM case, the wear of 
the prosthesis tends to be faster and more 
encompassing than anticipated. 
 
This has led to the release of large amounts of 
Cobalt and Chromium nanoparticles into 
patients’ bodies. 
 
Context 
 
In 2010, two hip prosthesis designs, called 
ASRTM, were taken off the market after having 
been implanted into nearly 100,000 patients. 
The reason: increased failure rates related to a 
range of adverse reactions to metal debris 
(Langton et al. 2010) which are likely to be the 
cause of widespread health problems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients are asked to trust medical and clinical 
sciences. Imagine the disappointment, fear and 
impact when medical interventions go wrong, 
leaving greater (including social) damage than 
they were intended to address in the first place. 
Reading: Barry (2001) Athlone Press; Curfman (2011) N Engl J Med 365;11; Hartwig et al (2003) Toxicology 193(1-2); Irwin (2001) Pub Underst Sci 
10(1); Langton et al (2010) J Bone Joint Surg (Br) 92-B; Reason (2002) Syst Pract Act Res 15(3); Skinner & Kay (2011) BMJ 342; The Royal College of 
Surgeons (2001). 
2. Nanoparticles from devices 
 
Both Chromium (Cr) and Cobalt (Co) 
nanoparticles are extremely reactive; they can 
cause damage to the DNA repair mechanism. 
(Hartwig et al. 2003). Their release is caused 
by greater wear of the articulating surfaces. 
 
 
 
 
 
 
Femoral neck fractures, pseudotumors, 
lesions and metallosis are symptoms of the 
heightened release of these nanoparticles into 
human tissue and blood.  
 
Whilst many physicians tend to wait until 
symptoms become apparent, increased Cr/Co 
levels in blood and serum are strong indicators 
for adverse effects even when the patient 
remains otherwise asymptomatic (no pain, 
mobile) for many years (Langton et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
3. Rationale of this project 
 
Patients are concerned and confused about 
the impact and effect of the nanoparticles in 
their bodies. The lack of a unified approach to 
responding to increased levels of ions, as well 
as the use of three (!) units of measurements, 
aggravate the situation. 
 
Over the last three decades, trust in science 
has eroded: BSE, GMO, grey goo and climate 
change debates show that whilst citizens are 
required to become more science-savvy, 
science, industry and policy seem to ignore or 
overlook the concerns of the publics. The case 
of ASRTM shows the potential danger of a 
similar trajectory developing in medicine. 
 
A range of governance and practice questions 
are raised by the ASRTM case, and voiced by 
patients: in how far are medical devices 
clinically tested before their introduction to the 
market – specifically their life cycle? Why has 
the regulation of medical devices not 
prevented this failure? And what is the role of 
the surgeon’s knowledge  and limits of 
obligation? 
 
 
4. Project Objectives 
 
The New England Journal of Medicine has 
branded the ASRTM recall a “public health 
nightmare”.  However, the needs and concerns of 
patients and their families are often not heard, or 
taken into account.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Our goals are: 
  
o Record and document patients’ experiences 
with failed hip replacements and in vivo 
nanoparticle release 
o Support patients in the North-East of England in 
developing links with other stakeholders in the 
UK, Europe and the world 
o Bring together engineers, Third Sector and 
Industry representatives with patients to discuss 
the ‘lessons learned’ from ASRTM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Methods & Outcomes 
 
Co-enquiry principles (Reason 2002) will inform 
this patient-centred project, supported by a range 
of public dialogue opportunities: 
o Website and Twitter 
o Public talks and Q&A events 
o A dedicated regional patient-centred workshop 
 
Outcomes will be available publicly on the website 
as film clips, DVDs, and mini posters. 
 
Funding 
This project is funded through an EPSRC Impact Award to further 
the research undertaken at Newcastle University by Dr Thomas 
Joyce. 
Despite clinical assumptions that after 
the removal of worn hip replacements 
the level of Cr and Co ions in the tissue 
and blood will decrease, widespread 
uncertainty about the long-term impacts 
of nanoparticles on the human body 
exists, but also real anxiety about illness, 
disability and livelihood. 
Taking a patient-centred approach, we will 
document and report their experiences, 
expectations and concerns in order to 
expand the discourse. We seek to open 
up underlying narratives that accompany 
the failure of medical devices, and the 
uncertainty of patients and practitioners 
about understanding, and dealing with, 
nanoparticles in the human body. 
 
